Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Farnier

Showing results (61-70 of 144) with videos related to

Pageof 15
Sort By:
Patient Preference and Adherence|August 19, 2021
Intentionality in adherence to long-term therapies. Results from an online survey of 3,001 patients with cardio-metabolic pathologies<i> </i>in FranceGérard Reach, Laurent Benarbia, Eric Bruckert, et al.
The American Journal of Cardiology|January 11, 2003
Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil)Michel Farnier, Michele Bortolini, Thomas Salko, et al.
Metabolism: Clinical and Experimental|May 27, 2008
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemiaDiane L Tribble, Michel Farnier, Geraldine Macdonell, et al.
Presse Medicale (Paris, France : 1983)|August 1, 2018
[Familial hypercholesterolemia: An under-diagnosed and under-treated disease. Survey of 495 physicians]Sophie Béliard, Jean-Pierre Rabès, Bertrand Cariou, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 2, 2024
Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial HypercholesterolemiaSophie Béliard, Samir Saheb, Stéphanie Litzler-Renault, et al.
Cardiovascular Drugs and Therapy|May 5, 2020
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension StudyGisle Langslet, G Kees Hovingh, John R Guyton, et al.
Clinical Drug Investigation|February 22, 2012
Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trialsMichel Farnier, David Marcereuil, Sophie De Niet, et al.
Lipids in Health and Disease|November 6, 2010
Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potencyMargus Viigimaa, Helena Vaverkova, Michel Farnier, et al.
Lipids in Health and Disease|May 20, 2015
Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based surveyMichel Krempf, Ross J Simpson, Dena Rosen Ramey, et al.
Atherosclerosis|October 10, 2014
Combination therapy in dyslipidemia: where are we now?Alberico L Catapano, Michel Farnier, JoAnne M Foody, et al.
Pageof 15

Showing results (61-70 of 144) with videos related to

Sort By:
Pageof 15
Patient Preference and Adherence|August 19, 2021
Intentionality in adherence to long-term therapies. Results from an online survey of 3,001 patients with cardio-metabolic pathologies<i> </i>in FranceGérard Reach, Laurent Benarbia, Eric Bruckert, et al.
The American Journal of Cardiology|January 11, 2003
Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil)Michel Farnier, Michele Bortolini, Thomas Salko, et al.
Metabolism: Clinical and Experimental|May 27, 2008
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemiaDiane L Tribble, Michel Farnier, Geraldine Macdonell, et al.
Presse Medicale (Paris, France : 1983)|August 1, 2018
[Familial hypercholesterolemia: An under-diagnosed and under-treated disease. Survey of 495 physicians]Sophie Béliard, Jean-Pierre Rabès, Bertrand Cariou, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 2, 2024
Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial HypercholesterolemiaSophie Béliard, Samir Saheb, Stéphanie Litzler-Renault, et al.
Cardiovascular Drugs and Therapy|May 5, 2020
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension StudyGisle Langslet, G Kees Hovingh, John R Guyton, et al.
Clinical Drug Investigation|February 22, 2012
Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trialsMichel Farnier, David Marcereuil, Sophie De Niet, et al.
Lipids in Health and Disease|November 6, 2010
Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potencyMargus Viigimaa, Helena Vaverkova, Michel Farnier, et al.
Lipids in Health and Disease|May 20, 2015
Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based surveyMichel Krempf, Ross J Simpson, Dena Rosen Ramey, et al.
Atherosclerosis|October 10, 2014
Combination therapy in dyslipidemia: where are we now?Alberico L Catapano, Michel Farnier, JoAnne M Foody, et al.
Pageof 15